Clinical Report: The Latest in Keratoconus Treatment
Overview
Recent advancements in keratoconus treatment have significantly improved patient outcomes, particularly through corneal crosslinking and scleral lenses. These innovations aim to halt disease progression and enhance visual rehabilitation, reducing the need for corneal transplantation.
Background
Keratoconus is a progressive degenerative disease of the cornea, often leading to severe visual impairment and the potential need for corneal transplantation. With a prevalence that may be higher than previously estimated, early detection and intervention are critical to managing this condition effectively. Recent developments in treatment strategies have shifted the focus from merely correcting vision to preventing disease progression.
Data Highlights
Corneal crosslinking has become the gold standard for halting keratoconus progression, with pivotal trials showing significant differences in maximum K reading (Kmax) between treated and sham groups after 12 months.
Key Findings
- Corneal crosslinking (epi-off) was approved in the U.S. in 2016, demonstrating over 2.5 diopters difference in Kmax change favoring treatment after 12 months.
- Patients treated with crosslinking showed more than 1.5 diopters of flattening, while sham-treated patients steepened by 1.0 diopters.
- Scleral lenses have evolved to provide excellent vision correction for nearly all keratoconus patients, reducing the need for transplants.
- Early treatment is crucial; patients should be referred for evaluation upon diagnosis to prevent progression.
- Ongoing research into epi-on crosslinking aims to reduce complications associated with epithelial removal.
- Combination therapy of crosslinking and scleral lenses has improved patient quality of life significantly.
Clinical Implications
Healthcare providers should prioritize early detection of keratoconus and consider corneal crosslinking as a first-line treatment to halt progression. Additionally, the use of scleral lenses can greatly enhance visual rehabilitation for patients, even those with significant corneal irregularities.
Conclusion
Advancements in keratoconus treatment, particularly corneal crosslinking and scleral lenses, have transformed management strategies, emphasizing the importance of early intervention to improve patient outcomes.
References
- Contact Lens Spectrum, Current Developments in Keratoconus Research, 2009 -- New findings shed light on a possible treatment for keratoconus
- Ophthalmology Management, VISUAL REHABILITATION FOR KERATOCONUS, 2022 -- Go beyond slowing or stopping progression
- The Second Global Consensus on Keratoconus at ESCRS - The ELZA Institute, 2025 -- Clinical guidance and consensus updates
- Contact Lens Spectrum — Current Developments in Keratoconus Research
- ophthalmology management — Adding Corneal Reshaping to Your Practice
- The Second Global Consensus on Keratoconus at ESCRS - The ELZA Institute
- Randomized, Controlled Study to Evaluate the Safety and Efficacy of Oxygen-Enriched Epithelium-On Corneal Cross-Linking for the Treatment of Keratoconus - PMC
- Accelerated versus conventional corneal collagen cross-linking for keratoconus: A meta-analysis of randomized controlled trials - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.